Direct-Acting Oral Anticoagulants as Emerging Treatment Options for Heparin-Induced Thrombocytopenia

Annals of Pharmacotherapy

Volumn 49, Issue 6, 2015, Pages 735-739

  Miyares, Marta A ^a   Davis, Kyle A ^a  

^a JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

apixaban; dabigatran; direct oral anticoagulants; heparin induced thrombocytopenia; rivaroxaban

Indexed keywords

APIXABAN; ARGATROBAN; DABIGATRAN; HEPARIN; RIVAROXABAN; THROMBOCYTE FACTOR 4; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ANTIGEN BINDING; DRUG INTERACTION; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LANGUAGE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOSIS; VENOUS THROMBOEMBOLISM; ADULT; CHEMICALLY INDUCED; METABOLISM; THROMBOCYTOPENIA; UNITED STATES;

ADULT; ANTICOAGULANTS; HEPARIN; HUMANS; PLATELET FACTOR 4; THROMBOCYTOPENIA; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84930590835     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015579424     Document Type: Review

References (25)

1. Amiral J,Bridey F,Dreyfus M, et al.Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.Thromb Haemost. 1992;681:95-96
2. Maccarana M,Lindahl U.Mode of interaction between platelet factor 4 and heparin.Glycobiology. 1993;3:271-277
3. Greinacher A,Pötzsch B,Amiral J,Dummel V,Eichner A,Mueller-Eckhardt C.Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4- heparin complex as the major antigen.Thromb Haemost. 1994;71:247-251
4. Kelton JG,Smith JW,Warkentin TE,Hayward CP,Denomme GA,Horsewood P.Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4.Blood. 1994;8311:3232-3239
5. Chong BH,Fawaz I,Chesterman CN,Berndt MC.Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets.Br J Haematol. 1989;732:235-240
6. Warkentin TE,Hayward CP,Boshkov LK, et al.Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.Blood. 1994;8411:3691-3699
7. Warkentin TE,Sheppard JI.Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists.Platelets. 1999;105:319-326
8. Warkentin TE,Levine MN,Hirsh J, et al.Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin.N Engl J Med. 1995;332:1330-1335
9. Warkentin TE,Roberts RS,Hirsh J,Kelton JG.An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients.Arch Intern Med. 2003;163:2518-2524
10. Greinacher A,Farner B,Kroll H,Kohlmann T,Warkentin TE,Eichler P.Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients.Thromb Haemost. 2005;94:132-135
11. Warkentin TE,Kelton JG.A 14-year study of heparin induced thrombocytopenia.Am J Med. 1996;101:502-507
12. Socher I,Kroll H,Jorks S,Santoso S,Sachs UJ.Heparin-independent activation of platelets by heparin-induced thrombocytopenia antibodies: a common occurrence.J Thromb Haemost. 2008;6:197-200
13. Lubenow N,Eichler P,Lietz T,Farner B,Greinacher A.Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies.Blood. 2004;104:3072-3077
14. Linkins LA,Dans AL,Moores LK, et al.Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012;141:e495S-530S
15. Hursting MJ,Lewis BE,Macfarlane DE,Hursting MJ,Lewis BE,Macfarlane DE.Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia.Clin Appl Thromb Hemost. 2005;11:279-287
16. Mavrakanas T,Bounameaux H.The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism.Pharmacol Ther. 2011;130:46-58
17. Krauel K,Hackbarth C,Fürll B,Greinacher A.Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.Blood. 2012;119:1248-1255
18. Fieland D,Taylor M.Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.Ann Pharmacother. 2012;46:e3
19. Mirdamadi A.Dabigatran, a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia.ARYA Atheroscler. 2013;9:112-114
20. Walenga JM,Prechel M,Jeske WP, et al.Rivaroxaban—an oral, direct Factor Xa inhibitor—has potential for the management of patients with heparin-induced thrombocytopenia.Br J Haematol. 2008;143:92-99
21. Hantson P,Lambert C,Hermans C.Rivaroxaban for arterial thrombosis related to heparin-induced thrombocytopenia.Blood Coagul Fibrinolysis. 2015;26:205-206
22. Ng HJ,Than H,Teo EC.First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia.Thromb Res. 2015;135:205-207
23. Linkins LA,Warkentin TE,Pai M, et al.Design of the rivaroxaban for heparin-induced thrombocytopenia study.J Thromb Thrombolysis. 2014;38:485-492
24. Walenga JM,Prechel M,Hoppensteadt D, et al.Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia.Clin Appl Thromb Hemost. 2013;19:482-487
25. Sharifi M,Freeman W,Bay C,Sharifi M,Breed C,Schwartz F.Treatment of heparin-induced thrombocytopenia with new oral anticoagulants.J Am Coll Cardiol. 2014;63:A2096